Wilms' tumor 1 peptide-major histocompatibility complex-T-cell receptor complex (WT1 pMHC-TCR complex)

The Wilms' tumor 1 (WT1) peptide-MHC-T-cell receptor (TCR) complex is a multi-component immunological structure that serves as a primary target for cancer immunotherapy. WT1 is a transcription factor that is highly overexpressed in many leukemias and solid tumors, making it a top-ranked tumor-associated antigen for therapeutic intervention (Cheever et al., 2009, PMID: 19276331). The complex forms when WT1-derived peptides—often modified as analogs to increase binding affinity for MHC molecules—are presented on the cell surface by Major Histocompatibility Complex (MHC) Class I or II molecules. These peptide-MHC (pMHC) complexes are then recognized by specific TCRs on T cells, triggering an immune response. Therapeutic strategies targeting this complex include peptide vaccines like Galinpepimut-S, which uses analog peptides to stimulate endogenous T cells, and TCR-engineered T-cell therapies that provide patients with T cells pre-programmed to recognize the WT1-pMHC complex (Maslak et al., 2018, PMID: 29305553; Chapuis et al., 2019, PMID: 30778011). The goal of these interventions is to induce selective lysis of WT1-positive malignant cells while minimizing damage to normal tissues such as the kidneys or hematopoietic stem cells where WT1 expression is low.

Other names

WT1-HLA-TCR complexWT1-specific TCR-pMHC complexWT1 antigen-MHC-TCR synapseWT1-MHC-TCR complex

Activation of the adaptive immune system, specifically CD8+ cytotoxic and CD4+ helper T cells, through the recognition of WT1-derived analog peptides presented by MHC molecules, leading to the targeted destruction of WT1-overexpressing tumor cells.